# Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.

> **NCT00318552** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 160 (—)

## Conditions studied

- Sepsis

## Interventions

- **DRUG:** Meropenem

## Key facts

- **NCT ID:** NCT00318552
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 160 (—)
- **Last updated:** 2017-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00318552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00318552, "Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00318552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*